<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">cxcl8</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CXCL8</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>cxcl8</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CXCL8" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">213 edges</a></td>
</tr>
</table>
The CXCL8 gene (Chemokine C-X-C Motif Ligand 8), also known as IL-8 (Interleukin-8), encodes a key pro-inflammatory chemokine that plays a central role in neutrophil recruitment, immune cell chemotaxis, and the inflammatory response. Located on chromosome 4q13.3, this gene produces a 99-amino acid polypeptide that acts through specific G-protein coupled receptors (CXCR1 and CXCR2) to orchestrate inflammatory responses throughout the body.
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">cxcl8</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CXCL8</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>cxcl8</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CXCL8" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">213 edges</a></td>
</tr>
</table>
The CXCL8 gene (Chemokine C-X-C Motif Ligand 8), also known as IL-8 (Interleukin-8), encodes a key pro-inflammatory chemokine that plays a central role in neutrophil recruitment, immune cell chemotaxis, and the inflammatory response. Located on chromosome 4q13.3, this gene produces a 99-amino acid polypeptide that acts through specific G-protein coupled receptors (CXCR1 and CXCR2) to orchestrate inflammatory responses throughout the body.
CXCL8 has emerged as a critical mediator in neuroinflammatory processes associated with Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. Elevated CXCL8 levels have been documented in the cerebrospinal fluid (CSF) and brain tissue of patients with these conditions, making it both a potential biomarker and therapeutic target[@blumdegen1995][@rentzos2002].
The CXCL8 gene (NCBI Gene ID: 3576) is positioned on chromosome 4q13.3 and spans approximately 5.2 kilobases. The gene consists of 4 exons that encode the mature 99-amino acid IL-8 protein, which is secreted as a monomer or dimer[@matsumoto1989].
The promoter region of CXCL8 contains multiple transcription factor binding sites that enable rapid induction in response to inflammatory stimuli:
IL-8 belongs to the CXC chemokine family, characterized by a specific Cys-Cys motif separated by one amino acid. The protein adopts a classic chemokine fold with an N-terminal loop, three anti-parallel β-sheets, and a C-terminal α-helix[@skelton1995].
Receptor Interactions:
CXCL8 contributes to AD pathogenesis through multiple mechanisms:
Neutrophil Recruitment to the Brain: In AD, the blood-brain barrier (BBB) becomes permeable, allowing peripheral immune cells to infiltrate the brain parenchyma. CXCL8 released by activated microglia and astrocytes recruits neutrophils, which release proteases and reactive oxygen species that can damage neurons and exacerbate amyloid pathology[@mcmanus2018][@eimer2019].
Synaptic Dysfunction: Elevated CXCL8 levels have been shown to impair synaptic plasticity and cognitive function. In vitro studies demonstrate that CXCL8 can reduce dendritic spine density and impair long-term potentiation (LTP) in hippocampal neurons through CXCR1/CXCR2 signaling[@licinio1999].
Amyloid Interaction: Amyloid-beta (Aβ) peptides can directly stimulate CXCL8 production in microglia and astrocytes, creating a positive feedback loop between amyloid pathology and neuroinflammation[@liu2013].
Clinical Evidence: Multiple studies have reported elevated CXCL8 in CSF and serum of AD patients compared to healthy controls. A meta-analysis confirmed that CXCL8 levels correlate with disease severity and cognitive decline[@ryu2019][@zhao2021].
In PD, CXCL8 plays several pathogenic roles:
Dopaminergic Neuron Toxicity: CXCL8 is elevated in the substantia nigra and striatum of PD patients. The chemokine can directly induce dopaminergic neuron death through activation of apoptotic signaling pathways. In vitro, CXCL8 exposure leads to mitochondrial dysfunction and increased reactive oxygen species (ROS) in dopaminergic cell lines[@wang2019][@tansey2022].
Microglial Activation: CXCL8 contributes to the pro-inflammatory activation of microglia in PD. Activated microglia release additional pro-inflammatory cytokines, creating a self-sustaining neuroinflammatory cascade that drives progressive dopaminergic degeneration[@sortwell2000].
Peripheral Inflammation: Elevated peripheral CXCL8 in PD patients correlates with disease severity and may reflect systemic inflammatory activation that contributes to CNS pathology[@chen2018].
BBB Permeability: CXCL8 can increase BBB permeability by disrupting tight junction proteins, facilitating the entry of peripheral immune cells into the CNS[@song2019].
Amyotrophic Lateral Sclerosis (ALS): CXCL8 is elevated in the CSF and serum of ALS patients. The chemokine is produced by activated astrocytes and contributes to motor neuron injury through neutrophil recruitment and pro-inflammatory signaling[@mitchell2009][@hu2019].
Multiple Sclerosis (MS): CXCL8 plays a pathogenic role in demyelination and lesion formation. The chemokine attracts neutrophils to active lesions, where they release myeloperoxidase and other damaging enzymes[@mennicken2009].
Huntington's Disease (HD): Elevated CXCL8 has been reported in HD patients and mouse models, contributing to the neuroinflammatory phenotype characteristic of the disease[@wild2019].
Frontotemporal Dementia (FTD): Recent studies have identified CXCL8 elevation in FTD patients, suggesting a shared neuroinflammatory mechanism with other neurodegenerative conditions[@chen2018a].
CXCL8 has been investigated as a potential biomarker for neurodegenerative disease diagnosis and progression:
Diagnostic Utility: CSF CXCL8 levels can distinguish AD patients from healthy controls with moderate sensitivity and specificity. However, overlap with other inflammatory conditions limits specificity[@obryant2018].
Progression Marker: Longitudinal studies suggest that CXCL8 levels correlate with cognitive decline rate in AD and motor progression in PD[@hu2012].
Therapeutic Response: CXCL8 may serve as a pharmacodynamic marker for anti-inflammatory therapies targeting neuroinflammation[@hall2020].
Several therapeutic strategies are being explored:
Neutralizing Antibodies: Anti-IL-8 monoclonal antibodies (e.g., BMS-986253) have been developed for cancer therapy and are being repurposed for neurodegenerative diseases[@damours2021].
CXCR1/CXCR2 Antagonists: Small molecule antagonists like reparixin and danirixin block IL-8 signaling and have shown efficacy in preclinical models of PD and ALS[@parajuli2019][@bhattacharya2020].
Natural Compounds: Several natural compounds with anti-inflammatory properties can reduce CXCL8 production, including curcumin, resveratrol, and omega-3 fatty acids[@jurcau2021].
Gene Therapy: Viral vector-based approaches to deliver CXCR2 decoy receptors are being explored in preclinical models[@zhang2022].
Blood-Brain Barrier Penetration: A significant challenge is developing CNS-penetrant inhibitors that can effectively block CXCL8 signaling in the brain[@bhatt2021].
Timing of Intervention: Given the complex role of inflammation in neurodegeneration, determining optimal timing for anti-CXCL8 interventions is critical. Early intervention may be most beneficial, while later-stage targeting might address the chronic neuroinflammatory component[@calsolaro2020].
Combination Approaches: CXCL8 targeting may be most effective when combined with other disease-modifying approaches, such as amyloid-targeting therapies in AD or dopaminergic therapies in PD[@akiyama2019].
CXCL8 signaling through CXCR1/CXCR2 activates multiple downstream pathways:
Gαi Signaling: Inhibition of adenylate cyclase, reduced cAMP, and activation of PI3K-Akt survival pathways (context-dependent)
Gβγ Signaling: Activation of PLC-β, leading to IP3 production and calcium release
MAPK Pathways: Activation of ERK1/2, p38, and JNK pathways that regulate gene expression and cell survival
NF-κB Activation: Pro-inflammatory gene expression including additional cytokines and chemokines[@waugh2008]
CXCL8 does not act in isolation but interacts with the broader inflammatory network:
Cytokine Network: CXCL8 works in concert with IL-1β, TNF-α, and IL-6 to amplify inflammatory responses
Chemokine Cascade: CXCL8 triggers production of additional chemokines (CXCL1, CXCL2, CCL2) that recruit more immune cells
Matrix Metalloproteinases (MMPs): CXCL8 can induce MMP-9 expression, leading to BBB breakdown and tissue remodeling[@galande2011]
Key questions remain regarding CXCL8 in neurodegeneration:
Multiple research groups are investigating:
Murine models of Alzheimer's and Parkinson's disease have provided important insights into CXCL8 pathogenesis:
The CXCL8 gene encodes a pivotal pro-inflammatory chemokine that plays significant roles in neurodegenerative disease pathogenesis. Through its actions on neutrophil recruitment, microglial activation, and direct neurotoxic effects, CXCL8 contributes to the neuroinflammatory cascade that drives disease progression in AD, PD, and related disorders.
The strong clinical evidence for CXCL8 elevation in neurodegenerative diseases, combined with mechanistic studies demonstrating causal contributions to pathology, makes it an attractive therapeutic target. While significant challenges remain in developing effective CNS-penetrant inhibitors, ongoing research continues to advance our understanding of CXCL8 biology and its potential for disease modification.
As the role of neuroinflammation in neurodegeneration becomes increasingly appreciated, CXCL8 represents a key node in the inflammatory network that may offer opportunities for therapeutic intervention.
The following diagram shows the key molecular relationships involving cxcl8 discovered through SciDEX knowledge graph analysis: